CoChat

hiPSC-Derived Cardiomyocyte Model of LQT2 Syndrome Derived from Asymptomatic and Symptomatic Mutation Carriers Reproduces Clinical Differences in Aggregates but Not in Single Cells

Open access

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Abstract

Mutations in the HERG gene encoding the potassium ion channel HERG, represent one of the most frequent causes of long QT syndrome type-2 (LQT2). The same genetic mutation frequently presents different clinical phenotypes in the family. Our study aimed to model LQT2 and study functional differences between the mutation carriers of variable clinical phenotypes. We derived human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) from asymptomatic and symptomatic HERG mutation carriers from the same family. When comparing asymptomatic and symptomatic single LQT2 hiPSC-CMs, results from allelic imbalance, potassium current density, and arrhythmicity on adrenaline exposure were similar, but a difference in Ca2+ transients was observed. The major differences were, however, observed at aggregate level with increased susceptibility to arrhythmias on exposure to adrenaline or potassium channel blockers on CM aggregates derived from the symptomatic individual. The effect of this mutation was modeled in-silico which indicated the reactivation of an inward calcium current as one of the main causes of arrhythmia. Our in-vitro hiPSC-CM model recapitulated major phenotype characteristics observed in LQT2 mutation carriers and strong phenotype differences between LQT2 asymptomatic vs. symptomatic were revealed at CM-aggregate level.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cells9051153

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Expression ratios of the wild type (WT) and the mutant (MUT) HERG alleles and localization of the HERG protein. (A) Allelic imbalance determination with the standard curve method. Standard data points were plotted as log2 (WT plasmid/MUT plasmid) ratios vs. corresponding mean ΔCt values (Ct(MUT)–Ct(WT)). Standard curve (dashed line) was determined with the least squares fit method. Expression ratios of the HERG alleles in the long QT syndrome type-2 (LQT2) samples were calculated using the mean ΔCt values of the samples and the standard curve equation. Mean ΔCt value for the LQT2 asymptomatic was calculated from the triplicates of the UTA.03412.LQT2 human-induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) samples and the mean ΔCt value for the symptomatic was calculated from the UTA.03809.LQT2 and the UTA.03810.LQT2 hiPSC-CM samples. Error bars indicate the standard errors of ΔCt means. The locations of the data points indicate that the HERG (KCNH2) alleles are expressed in all three cell lines with the wild type/mutant allele ratio somewhere between 1:2 and 1:1. The allelic imbalance assay was repeated with another set of samples of the three cell lines, yielding similar results (data not shown). (B) The fluorescent mScarlet-tagged WT and MUT HERG alleles expressed in the HEK293 cells indicated the increased localization to the cell membrane in the wildtype (WT) and the increased cytoplasmic localization of mutant HERG (MUT HERG) (transmitted light images added as inset).
Figure 1 Expression ratios of the wild type (WT) and the mutant (MUT) HERG alleles and localization of the HERG protein. (A) Allelic imbalance determination with the standard curve method. Standard data points were plotted as log2 (WT plasmid/MUT plasmid) ratios vs. corresponding mean ΔCt values (Ct(MUT)–Ct(WT)). Standard curve (dashed line) was determined with the least squares fit method. Expression ratios of the HERG alleles in the long QT syndrome type-2 (LQT2) samples were calculated using the mean ΔCt values of the samples and the standard curve equation. Mean ΔCt value for the LQT2 asymptomatic was calculated from the triplicates of the UTA.03412.LQT2 human-induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) samples and the mean ΔCt value for the symptomatic was calculated from the UTA.03809.LQT2 and the UTA.03810.LQT2 hiPSC-CM samples. Error bars indicate the standard errors of ΔCt means. The locations of the data points indicate that the HERG (KCNH2) alleles are expressed in all three cell lines with the wild type/mutant allele ratio somewhere between 1:2 and 1:1. The allelic imbalance assay was repeated with another set of samples of the three cell lines, yielding similar results (data not shown). (B) The fluorescent mScarlet-tagged WT and MUT HERG alleles expressed in the HEK293 cells indicated the increased localization to the cell membrane in the wildtype (WT) and the increased cytoplasmic localization of mutant HERG (MUT HERG) (transmitted light images added as inset).CC BY · PubMed Central
Figure 2 IKr densities: (A) IKr currents were obtained as 1 µM E-4031 sensitive currents with the used protocol. Inset: the voltage protocol used to elicit the IKr current. (B,C) Current-voltage plot of the peak IKr current densities and the tail IKr densities respectively from controls (black), for the LQT2 asymptomatic (red), and symptomatic (blue) hiPSC-CMs. Values inside parentheses indicate the number of hiPSC-CMs analyzed. Data is presented as the mean ± SEM, (*) p < 0.05, (**) p < 0.01 and (***) p < 0.001 between control and asymptomatic and (#) p < 0.05, (##) p < 0.01 and (###) p < 0.001 between control and symptomatic hiPSC-CMs.
Figure 2 IKr densities: (A) IKr currents were obtained as 1 µM E-4031 sensitive currents with the used protocol. Inset: the voltage protocol used to elicit the IKr current. (B,C) Current-voltage plot of the peak IKr current densities and the tail IKr densities respectively from controls (black), for the LQT2 asymptomatic (red), and symptomatic (blue) hiPSC-CMs. Values inside parentheses indicate the number of hiPSC-CMs analyzed. Data is presented as the mean ± SEM, (*) p < 0.05, (**) p < 0.01 and (***) p < 0.001 between control and asymptomatic and (#) p < 0.05, (##) p < 0.01 and (###) p < 0.001 between control and symptomatic hiPSC-CMs.CC BY · PubMed Central
Figure 3 LQT2 hiPSC-CM shows increased calcium transient abnormalities. (A) Response of the control, the LQT2 asymptomatic and the symptomatic hiPSC-CMs to application of 10 nM adrenaline. (B) Percentage of CMs showing arrhythmia at baseline (BL) and during 10 nM adrenaline (Adr 10nM) perfusion. (C) Comparison of type of arrhythmia observed at baseline and under adrenaline (Adr) in the control, the LQT2 asymptomatic and the symptomatic CMs. (D) Representative arrhythmia observed in the control, the LQT2 asymptomatic and the symptomatic hiPSC-CMs Ca2+ transients. LQT2 asymptomatic CMs have most occurrences of oscillations and low amplitude peaks, while symptomatic CMs have quite equal amounts of all the five kinds of abnormalities but more delay in rise and decay phase than the LQT2 asymptomatic. RG = Regular, OS = oscillations and multiple peaks, LP = low amplitude peaks, PL = plateau abnormality/delay in decay, RD = rise delay, VA = varying amplitude. (E–L) Ca2+ imaging parameters at baseline and in the presence of 10 nM adrenaline. Data is presented for n = 68, 78, 44 for the control, the LQT2 asymptomatic, and the symptomatic respectively, as the mean ± SEM, (*) p < 0.05, (**) p < 0.01 and (***) p < 0.001.
Figure 3 LQT2 hiPSC-CM shows increased calcium transient abnormalities. (A) Response of the control, the LQT2 asymptomatic and the symptomatic hiPSC-CMs to application of 10 nM adrenaline. (B) Percentage of CMs showing arrhythmia at baseline (BL) and during 10 nM adrenaline (Adr 10nM) perfusion. (C) Comparison of type of arrhythmia observed at baseline and under adrenaline (Adr) in the control, the LQT2 asymptomatic and the symptomatic CMs. (D) Representative arrhythmia observed in the control, the LQT2 asymptomatic and the symptomatic hiPSC-CMs Ca2+ transients. LQT2 asymptomatic CMs have most occurrences of oscillations and low amplitude peaks, while symptomatic CMs have quite equal amounts of all the five kinds of abnormalities but more delay in rise and decay phase than the LQT2 asymptomatic. RG = Regular, OS = oscillations and multiple peaks, LP = low amplitude peaks, PL = plateau abnormality/delay in decay, RD = rise delay, VA = varying amplitude. (E–L) Ca2+ imaging parameters at baseline and in the presence of 10 nM adrenaline. Data is presented for n = 68, 78, 44 for the control, the LQT2 asymptomatic, and the symptomatic respectively, as the mean ± SEM, (*) p < 0.05, (**) p < 0.01 and (***) p < 0.001.CC BY · PubMed Central
Figure 4 LQT2 hiPSC-CMs from the symptomatic patients presenting with increased arrhythmia on adrenaline application (A) Representative field potential traces from the control, the LQT2 asymptomatic and the symptomatic aggregates at baseline. The red arrows depict the end point of the repolarization duration, i.e., the field potential duration (FPD); the FPD was calculated from the start of the depolarization wave until the repolarization wave reaching the base. (B,C) The scatter-dot plots show the beat rate and the corrected field potential durations (cFPDs) from the control, the LQT2 asymptomatic and the symptomatic (labelled as (C,A and S with black, red and blue colors respectively), the boxes show the mean and SEM, for n = 62, 46, 38, respectively, for both the plots. (D) Percentage of aggregates showing arrhythmia at baseline, vehicle and under 100 nM, 300 nM, 600 nM and 1 µM adrenaline application; n numbers for the control, the LQT2 asymptomatic and the symptomatic; Bl-Veh n = 20, 19, 20, Bl–Adr100nM n = 22, 17, 22, Bl-Adr300nM n= 20, 16, 23, BL-Adr600nM n = 23, 19, 22 and BL-Adr1µM n = 24, 18, 21, respectively. (E) Comparison of the types of arrhythmia observed at baseline and under adrenaline (types elaborated below). (F) Representative field potentials and characteristic arrhythmia observed in the control, the LQT2 asymptomatic and the symptomatic hiPSC-CM aggregates at baseline and after the application of adrenaline. (a) IMT = irregular monomorphic tachycardiac-like arrhythmia and variation of field potential beats, (b) ALT = alternans, (c) PEBs = premature ectopic beats, (d) EADs = early after polarization-like arrhythmia, (e) RA = Repolarization abnormality with monomorphic arrhythmia (f) MMTA = Monomorphic triggered activity-like arrhythmia (g) NSVT = Non-sustained ventricular tachycardia-like arrhythmia, (h) NSVF = Non-sustained ventricular fibrillation-like arrhythmia. The red arrows point to distinguish the types of arrhythmia for clarity purposes.
Figure 4 LQT2 hiPSC-CMs from the symptomatic patients presenting with increased arrhythmia on adrenaline application (A) Representative field potential traces from the control, the LQT2 asymptomatic and the symptomatic aggregates at baseline. The red arrows depict the end point of the repolarization duration, i.e., the field potential duration (FPD); the FPD was calculated from the start of the depolarization wave until the repolarization wave reaching the base. (B,C) The scatter-dot plots show the beat rate and the corrected field potential durations (cFPDs) from the control, the LQT2 asymptomatic and the symptomatic (labelled as (C,A and S with black, red and blue colors respectively), the boxes show the mean and SEM, for n = 62, 46, 38, respectively, for both the plots. (D) Percentage of aggregates showing arrhythmia at baseline, vehicle and under 100 nM, 300 nM, 600 nM and 1 µM adrenaline application; n numbers for the control, the LQT2 asymptomatic and the symptomatic; Bl-Veh n = 20, 19, 20, Bl–Adr100nM n = 22, 17, 22, Bl-Adr300nM n= 20, 16, 23, BL-Adr600nM n = 23, 19, 22 and BL-Adr1µM n = 24, 18, 21, respectively. (E) Comparison of the types of arrhythmia observed at baseline and under adrenaline (types elaborated below). (F) Representative field potentials and characteristic arrhythmia observed in the control, the LQT2 asymptomatic and the symptomatic hiPSC-CM aggregates at baseline and after the application of adrenaline. (a) IMT = irregular monomorphic tachycardiac-like arrhythmia and variation of field potential beats, (b) ALT = alternans, (c) PEBs = premature ectopic beats, (d) EADs = early after polarization-like arrhythmia, (e) RA = Repolarization abnormality with monomorphic arrhythmia (f) MMTA = Monomorphic triggered activity-like arrhythmia (g) NSVT = Non-sustained ventricular tachycardia-like arrhythmia, (h) NSVF = Non-sustained ventricular fibrillation-like arrhythmia. The red arrows point to distinguish the types of arrhythmia for clarity purposes.CC BY · PubMed Central
Figure 5 The effects of the IKr and IKs blockers (A,B) The plots show the responses of the control, the LQT2 asymptomatic and the symptomatic hiPSC-CM aggregates to the IKr blocker E4031 at 300 nM and the occurrence of major arrhythmia for the vehicle (distilled H2O) n = 26, 18, 19 respectively, and for 300 nM E4031 n = 39, 17, 24, respectively. (C,D) Responses of the control, the LQT2 asymptomatic and the symptomatic hiPSC-CM aggregates to the IKs blocker JNJ303 300 nM and the occurrence of major arrhythmia for the vehicle (DMSO) n = 9, 3, 11, respectively, and 300 nM JNJ303 n = 27, 13, 12, respectively. Data is presented as mean ± SEM, (*) p < 0.05 and (***) p < 0.001 compared between Long QT asymptomatic or symptomatic and control and (#) p <0.05, compared on all three lines by ANOVA. (E,F) Representative field potentials and the characteristic arrhythmia observed in the control, the LQT2 asymptomatic and the symptomatic hiPSC-CM aggregates at baseline (black) and after application of E4031 and JNJ303 (red); the prolongation in FPD is marked by orange and blue lines, whereas EAD-like arrhythmias and premature ectopic beats (PEBs) are marked with black arrowheads.
Figure 5 The effects of the IKr and IKs blockers (A,B) The plots show the responses of the control, the LQT2 asymptomatic and the symptomatic hiPSC-CM aggregates to the IKr blocker E4031 at 300 nM and the occurrence of major arrhythmia for the vehicle (distilled H2O) n = 26, 18, 19 respectively, and for 300 nM E4031 n = 39, 17, 24, respectively. (C,D) Responses of the control, the LQT2 asymptomatic and the symptomatic hiPSC-CM aggregates to the IKs blocker JNJ303 300 nM and the occurrence of major arrhythmia for the vehicle (DMSO) n = 9, 3, 11, respectively, and 300 nM JNJ303 n = 27, 13, 12, respectively. Data is presented as mean ± SEM, (*) p < 0.05 and (***) p < 0.001 compared between Long QT asymptomatic or symptomatic and control and (#) p <0.05, compared on all three lines by ANOVA. (E,F) Representative field potentials and the characteristic arrhythmia observed in the control, the LQT2 asymptomatic and the symptomatic hiPSC-CM aggregates at baseline (black) and after application of E4031 and JNJ303 (red); the prolongation in FPD is marked by orange and blue lines, whereas EAD-like arrhythmias and premature ectopic beats (PEBs) are marked with black arrowheads.CC BY · PubMed Central
Figure 6 Drug responses of healthy controls vs. LQT2 hiPSC-CMs in-silico. (A) Comparison of AP from the healthy control hiPSC (black) and the LQT2 (blue) showing a prolongation of 20.53% in APD90. (B) Effect of p.L552S HERG mutation on the densities of K+ currents, with a reduction in IKr, but an increase in IKs. (C,D) Effect of the IKr blocker E4031 at 0 µM (black), 0.1 µM (yellow), 0.2 µM (orange) and 0.3 µM (red) on AP morphology (left panel), in healthy control hiPSC and LQT2, and the effect of the IKr block 0%–100% on the L-type calcium channel (middle panel) and the sodium channel exchanger NCX current (Sodium calcium exchanger- calcium efflux current) (right). (E,F) Effect of the IKs blocker JNJ303 on the control (top) and the LQT2 (bottom) with baseline as (solid line) 0.3 µM JNJ303 (dotted line) on the AP morphology. Finally, the effect of the IKs block 0%–100% on the densities of IKr and IKs, shown using black solid and red dotted lines for the controls and blue solid and pink dotted lines for the LQT2, respectively.
Figure 6 Drug responses of healthy controls vs. LQT2 hiPSC-CMs in-silico. (A) Comparison of AP from the healthy control hiPSC (black) and the LQT2 (blue) showing a prolongation of 20.53% in APD90. (B) Effect of p.L552S HERG mutation on the densities of K+ currents, with a reduction in IKr, but an increase in IKs. (C,D) Effect of the IKr blocker E4031 at 0 µM (black), 0.1 µM (yellow), 0.2 µM (orange) and 0.3 µM (red) on AP morphology (left panel), in healthy control hiPSC and LQT2, and the effect of the IKr block 0%–100% on the L-type calcium channel (middle panel) and the sodium channel exchanger NCX current (Sodium calcium exchanger- calcium efflux current) (right). (E,F) Effect of the IKs blocker JNJ303 on the control (top) and the LQT2 (bottom) with baseline as (solid line) 0.3 µM JNJ303 (dotted line) on the AP morphology. Finally, the effect of the IKs block 0%–100% on the densities of IKr and IKs, shown using black solid and red dotted lines for the controls and blue solid and pink dotted lines for the LQT2, respectively.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Cited by

See all 34

Metadata

Authors
Shah, D., Prajapati, C., Penttinen, K., Cherian, R. M., Koivumäki, J. T., Alexanova, A., Hyttinen, J., & Aalto-Setälä, K.
Affiliations
  • Tampere University (FI)
  • Faculty of Medicine and Health Technology and BioMediTech Institute, Tampere University, 33520 Tampere, Finland
Corresponding author
Shah, Disheet
Venue
Cells
Publisher
MDPI AG
Published
2020-05-07
Volume
9
Issue
5
Pages
1153
ISSN
2073-4409 (ISSN-L)
OpenAlex
W3020941314
Cited by
31
References
57
Citations by year
2026: 6 · 2025: 1 · 2024: 3 · 2023: 5 · 2022: 6 · 2021: 5 · 2020: 5
FWCI
3.25
Type
journal article
Language
en
Open access
Locations
  • Cells (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Tampere University Institutional Repository (Tampere University) (submittedVersion, cc-by)
Funders
  • Yrjö Jahnssonin Säätiö
  • Aarne Koskelon Säätiö
  • Suomen Kulttuurirahasto
  • Paavo Nurmen Säätiö
  • Pirkanmaan Sairaanhoitopiiri
  • Opetushallitus
  • Pirkanmaan Rahasto
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
Keywords
long QT syndrome type 2, hERG, hiPSC-derived cardiomyocytes, arrhythmia susceptibility, adrenaline-induced arrhythmia, calcium transients, asymptomatic mutation carriers, in silico modeling
MeSH terms
Adult, Alleles, Cell Aggregation, Female, Humans, Long QT Syndrome, Male, Middle Aged, Models, Biological, Mutation, Ion Channel Gating, Case-Control Studies, Myocytes, Cardiac, Induced Pluripotent Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: hiPSC-Derived Cardiomyocyte Model of LQT2 Syndrome Derived from Asymptomatic and Symptomatic Mutation Carriers Reproduces Clinical Differences in Aggregates but Not in Single Cells. https://app.cochat.ai/papers/10.3390/cells9051153
The paper
Shah, D., Prajapati, C., Penttinen, K., Cherian, R. M., Koivumäki, J. T., Alexanova, A., Hyttinen, J., & Aalto-Setälä, K. (2020). hiPSC-Derived Cardiomyocyte Model of LQT2 Syndrome Derived from Asymptomatic and Symptomatic Mutation Carriers Reproduces Clinical Differences in Aggregates but Not in Single Cells. Cells. https://doi.org/10.3390/cells9051153

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.